Microvascular Therapeutics is attending the Contrast Media Research Meeting in Santa Fe this week.

emeuillet0

13 hours ago

1 min read

Microvascular Therapeutics is attending the Contrast Media Research Meeting in Santa Fe this week. Our CEO, Dr Unger is presenting pre-clinical and clinical results for CardiSon, our next generation of ultrasound enhancing agent and our COO/CSO, Dr Meuillet is presenting pre-clinical results for Solv, a novel Phase Shift Microbubble for the treatment of microvascular obstruction.

Recent Posts

See All

Microvascular Therapeutics Appoints George Kokke to Board of Directors

Veteran family office executive and healthcare investor brings more than 30 years of investment, finance, and board experience.

Microvascular Therapeutics Appoints Charles Garrison, MD, to Scientific Advisory Board

Experienced pathologist, biotechnology entrepreneur, and life sciences investor will advise MVT on scientific and medical development

MVT's Nanobubbles Enable Non-Thermal Focused Ultrasound Ablation in Preclinical Brain Tumor Study

University of Utah researchers use MVT-101 phase-shift nanobubbles with focused ultrasound and MRI to confirm treatment location

Comments